Robbins Geller Rudman & Dowd LLP announced that investors who purchased Grail common stock between May 13, 2025 and February 19, 2026 have until Tuesday, August 4, 2026 to seek appointment as lead plaintiff in a securities class action lawsuit against the company. The lawsuit alleges that Grail and certain executives made false or misleading statements about the likelihood of achieving the primary endpoint in its NHS-Galleri cancer screening trial, concealing adverse facts that reduced the probability of success. On February 19, 2026, Grail disclosed that the trial did not meet its primary endpoint of a statistically significant reduction in late-stage cancers, causing its stock price to drop more than 50%. The case, captioned Robbins v. Grail, Inc., was filed in the Northern District of California under the Securities Exchange Act of 1934.
GRAIL, LLCSecurities class action lawsuit alleging false statements about trial endpoint; stock dropped >50% on disclosure of trial failure.